Vincent Mandola, MD
Sports Medicine · Pearland, TXNPI 1013352251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Amgen at 32.1% of the total. Reporting peaked in 2019 at $689 and has fallen 97.6% since, to $17 in 2025. That places this record below the midpoint for sports medicine clinicians in TX, where the typical reported total is $1,700.
Across 48 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$409
- Pacira Therapeutics, Inc.$225
- Merz North America, Inc.$157
- Biotissue Holdings Inc.$150
- AstraZeneca$66
- Optinose US, Inc.$39
- plus $229 from 10 others
What the payments were for
- Food & beverage$1,275100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 23 | $409 |
| Pacira Therapeutics, Inc. | 2 | $225 |
| Merz North America, Inc. | 2 | $157 |
| Biotissue Holdings Inc. | 3 | $150 |
| AstraZeneca | 4 | $66 |
| Optinose US, Inc. | 2 | $39 |
| Bioventus LLC | 2 | $37 |
| Nevro Corp. | 1 | $32 |
| Merck | 2 | $27 |
| AbbVie | 1 | $26 |
| Exact Sciences | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zilretta$225
How this compares
$1,275 in reported general payments places this provider in the 45th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $54,918 |
| EliquisApixaban | 40 | $34,321 |
| FarxigaDapagliflozin Propanediol | 26 | $28,570 |
| JardianceEmpagliflozin | 21 | $21,433 |
| TrulicityDulaglutide | 12 | $17,794 |
| MounjaroTirzepatide | 12 | $16,233 |
| JanuviaSitagliptin Phosphate | 13 | $11,840 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,625 |
| SynthroidLevothyroxine Sodium | 16 | $1,453 |
| Celecoxib | 71 | $1,370 |
| Atorvastatin Calcium | 153 | $1,208 |
| Rosuvastatin Calcium | 84 | $1,057 |
| Doxycycline Monohydrate | 33 | $955 |
| Lisinopril | 136 | $911 |
| Famotidine | 51 | $858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $22 | $54,91845 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $11 | $34,02724 claims |
| AstraZenecaFarxiga | $66 | $28,57026 claims |
| MerckJanuvia | $27 | $11,84013 claims |
| AbbVieSynthroid | $26 | $1,45316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 437 sports medicine providers in Texas.
Other sports medicine in Pearland
- Leon PaulosPearland$289K
- Evan MeeksPearland$60K
- Thomas DeberardinoSan Antonio$3.5M
- Robert ScheinbergDallas$2.2M
- Walter LoweHouston$1.4M
- Reed BartzSunnyvale$1.2M
- James GregoryHouston$565K
- John McDonaldAustin$499K
- James McKinleyTyler$305K
- Kelechi OkorohaDallas$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.